Full-Time

Scientist/Senior Engineer

Commercial Drug Product

Updated on 9/10/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$111.9k - $151.4k/yr

+ Annual bonus + Stock-based long-term incentives

Thousand Oaks, CA, USA

In Person

Domestic and international travel may be required.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Biophysics
GMP
Biochemistry
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master’s degree and 4 years of Operations, Process Development, Scientific, or Engineering experience, or a bachelor’s degree and 6 years of Operations, Process Development, Scientific, or Engineering experience.
  • Experience supporting parenteral drug product development and manufacturing, including liquid and/or lyophilized presentations.
  • Hands-on or technical experience with fill/finish unit operations such as formulation, mixing, sterile filtration, filling, capping, lyophilization, visual inspection, and process scale-up.
  • Experience serving as a technical lead, SKU lead, process lead, or commercialization lead for late-stage or commercial drug product programs.
  • Experience with process characterization, scale-down model development, scale-up, technology transfer, process validation support, and commercial manufacturing support.
  • Familiarity with aseptic processing, current good manufacturing practices, International Council for Harmonisation guidelines, regulatory filings, pre-approval inspections, and good manufacturing practice documentation.
  • Experience with non-conformance investigations, root cause analysis, product impact assessments, process capability analysis, statistical process control, design of experiments, and risk assessment tools.
  • Strong understanding of how process parameters, equipment, raw materials, scale, site differences, and process-related stresses can impact product quality.
  • Ability to analyze large and complex data sets using statistical tools, process monitoring approaches, modeling, or digital systems.
  • Familiarity with artificial intelligence-enabled tools or advanced analytics for process characterization, process monitoring, knowledge management, and data-driven decision-making.
  • Ability to work effectively in a matrixed, global team environment and influence across functions without direct authority.
  • Strong communication, technical writing, facilitation, organization, and stakeholder-management skills.
  • Ability to manage dynamic information, prioritize across multiple programs or SKUs, and drive decisions in a fast-paced environment.
  • Ability to travel domestically and internationally as business needs require.
Responsibilities
  • Serve as the Drug Product SKU Lead for assigned commercial or late-stage pipeline products, providing end-to-end technical ownership for formulation, fill/finish, presentation, and lifecycle management activities.
  • Lead or support commercial technology transfers, including facility-fit assessments, make-a-batch assessments, process gap analyses, risk assessments, process characterization studies, technical documentation, and on-site manufacturing support.
  • Provide technical leadership for parenteral drug product unit operations, including formulation, mixing, sterile filtration, filling, capping, lyophilization, visual inspection, and related equipment/process interfaces.
  • Plan, design, execute, and document laboratory, offline, and on-site studies related to drug product process development, process characterization, scale-up, process robustness, and lifecycle management.
  • Provide technical leadership for assigned SKUs by integrating process understanding, product quality attributes, manufacturing performance, analytical data, regulatory commitments, and site capabilities.
  • Support clinical and commercial manufacturing operations through process capability analysis, troubleshooting, root cause analysis, non-conformance investigations, corrective and preventive actions, and product impact assessments.
  • Author and review technical protocols, study reports, process transfer documents, product impact assessments, regulatory submission sections, responses to regulatory questions, and lifecycle management documentation.
  • Partner with manufacturing sites and cross-functional teams to assess and implement process changes, equipment changes, raw material changes, scale changes, site transfers, and process improvements while ensuring product quality and supply continuity.
  • Apply scientific and engineering principles, including biochemistry, biophysics, statistics, and chemical engineering, to solve complex technical challenges.
  • Use data-driven approaches, statistical analysis, process monitoring, modeling, and advanced digital or artificial intelligence-enabled tools to improve process understanding, manufacturing robustness, and technology transfer efficiency.
  • Lead or participate in global cross-functional teams in a highly matrixed environment, influencing decision-making, communicating risks, and driving alignment across stakeholders.
  • Deliver clear technical updates, progress reports, risk assessments, and recommendations to management, program teams, governance forums, and manufacturing partners.
  • Build and sustain partnerships with Drug Product Technologies, Attribute Sciences, Manufacturing, Quality, Regulatory, Engineering, Supply Chain, and site teams to ensure alignment between product needs, process requirements, and site capabilities.
Desired Qualifications
  • Three or more years of experience in drug product process development, process engineering, commercialization, manufacturing sciences, or lifecycle management within the pharmaceutical or biotechnology industry.
  • A Master of Science or Doctor of Philosophy in Chemical Engineering, Biomedical Engineering, Pharmaceutical Sciences, Pharmaceutics, Chemistry, Biochemistry, Biotechnology, Material Science, or a related technical discipline.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.